Drug · Small Molecule

Tanespimycin

CI-DRUG-00000574Explore in graph →NCIt C37899 CHEMBL109480 CIViC Phase 3

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	2	35	—	—	1998-08
Multiple Myeloma	Phase3	Phase 3	2	2	—	—	2007-08
Non-Hodgkin Lymphoma	Phase3	Phase 3	2	8	—	—	1999-06
Hodgkin Lymphoma	Phase2	Phase 2	0	4	—	—

Curated evidence

Clinical evidence (6)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ALK G1202R + ALK Fusion1
Tanespimycin	Lung Non-Small Cell Carcinoma

Clinical trials

Trials with this intervention (35)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–35 of 35 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00118092	17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy	completed	Phase 2	17	National Cancer Institute (NCI)NIH	1	Apr 18, 2017	clinicaltrials
NCT00118248	Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer	completed

Molecule

Record

Kind: Small Molecule
Mechanism: Heat shock protein HSP90 inhibitor
Targets: 2 genes
Aliases: 17aag, 17-AAG, 17-(Allylamino)-17-demethoxygeldanamycin, 17-Demethoxy-17-(2-propenylamino)geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin, 17-N-allylamino-17-demethoxy Geldanamycin, BMS-722782, CNF-1010, CNF1010, Geldanamycin, 17-allylamino-17-demethoxy-, KOS-953, NSC-330507, Tanespimicina, Tanespimycin, Tanespimycine

Data updated 22 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.

PIK3CA Mutation2
Pictilisib + Tanespimycin + TrametinibSubstitutes	Malignant Head and Neck NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	accepted	EID1364 6 head and neck cancer cell lines were tested for Response to 17-AAG, GDC-0941. Two of the cell lines did not carry PIK3CA mutations. No clear difference was shown between PIK3CA-mutant and wild-type … (full text at CIViC) PMID 25855885 · Wirtz et al., 2015 · Open in CIViC	civic
Pictilisib + TanespimycinSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Sensitivity Response	2	accepted	EID1358 Analysis of drug response data from the Sanger center cell line screen. Cell lines with either PI3K and/or PTEN mutations did not show a significant difference in response to class I PI3K inhibitor GD… (full text at CIViC) PMID 25855885 · Wirtz et al., 2015 · Open in CIViC	civic